IPP Bureau
Takeda posts strong Phase 3 win for oral psoriasis drug
By IPP Bureau - December 21, 2025
Takeda said zasocitinib was generally well tolerated, with a safety profile consistent with earlier studies
Soligenix publishes promising Phase 2a data for SGX945 in Behcet's Disease
By IPP Bureau - December 21, 2025
SGX945 delivered beneficial effects in 7 of 8 patients suffering from painful oral ulcers
Qihan Biotech launches first-in-human trial of off-the-shelf CAR-T therapy for refractory lupus
By IPP Bureau - December 21, 2025
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
EMA grants orphan drug status to Sanofi’s Efdoralprin Alfa for rare lung disease
By IPP Bureau - December 20, 2025
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
Briefs: APL Healthcare, Biocon, USFDA, Sun Pharma and Clean Fino-Chem
By IPP Bureau - December 20, 2025
USFDA determines Sun Pharma's Baska facility inspection classification as OAI
Cosette Pharmaceuticals launches first generic CIPRO HC with 180 Days market exclusivity
By IPP Bureau - December 20, 2025
The approval comes with 180 days of Competitive Generic Therapy (CGT) exclusivity,
GSK’s Exdensur gains FDA nod for severe asthma with just two doses a year
By IPP Bureau - December 20, 2025
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
SandboxAQ, MapLight team up to target novel CNS therapy with AI-driven drug discovery
By IPP Bureau - December 20, 2025
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
Pfizer and Cipla forge exclusive marketing and distribution pact for key brands in India
By IPP Bureau - December 20, 2025
This marks the first partnership between Pfizer and Cipla in India
Fortis invests Rs. 840 crore for 300+ beds in Bengaluru
By IPP Bureau - December 20, 2025
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
Alembic announces USFDA final approval for Travoprost Ophthalmic Solution USP, 0.004%
By IPP Bureau - December 20, 2025
Travoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
Lupin signs exclusive licensing pact with Neopharmed for Plasil in Philippines and Brazil
By IPP Bureau - December 19, 2025
This agreement will enhance Lupin’s gastroenterology portfolio and expand its presence in emerging markets
Gilead’s new HIV therapy shows promising Phase 3 results
By IPP Bureau - December 19, 2025
The study found BIC/LEN to be statistically non-inferior to BIKTARVY, Gilead’s current standard-of-care therapy
Immunome’s Varegacestat shows dramatic results in Phase 3 desmoid tumor trial
By IPP Bureau - December 19, 2025
The trial met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival
